NYXH
Nyxoah SA

377
Mkt Cap
$168.99M
Volume
26,787.00
52W High
$11.87
52W Low
$4.35
PE Ratio
-2.21
NYXH Fundamentals
Price
$5.07
Prev Close
$5.08
Open
$5.06
50D MA
$5.47
Beta
0.49
Avg. Volume
67,969.74
EPS (Annual)
-$1.96
P/B
2.20
Rev/Employee
$26,635.75
Loading...
Loading...
News
all
press releases
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for
Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago
News Placeholder
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
NYXH's first U.S. commercial use of its Genio system signals strong physician demand and sets the stage for broad adoption in sleep apnea care.
Zacks·29d ago
News Placeholder
US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder
Nyxoah CEO Olivier Taelman said that the company has also trained surgeons, obtained Value Analysis Committee approvals, and achieved successful coverage from major payors.
Stocktwits·30d ago
News Placeholder
Nyxoah Expands in the Middle East to Provide Wider Access to Genio
NYXH expands in the Middle East after Abu Dhabi's first Genio implant, aiming to broaden access for OSA patients.
Zacks·1mo ago
News Placeholder
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.
Zacks·3mo ago
News Placeholder
Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates
Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +5.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Privia Health (PRVA) Misses Q2 Earnings Estimates
Privia Health (PRVA) delivered earnings and revenue surprises of -60.00% and +11.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates
Outset Medical (OM) delivered earnings and revenue surprises of +52.27% and +5.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates
Zacks·6mo ago

Latest NYXH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.